• The Hiding Hepatitis Viruses A to E: Why We Can’t Eradicate them all, yet.
    Jun 25 2026

    The World Health Organization (WHO) has set an ambitious goal to eliminate viral hepatitis by 2030. But with over 250 million people living with Hepatitis B globally, why are we still falling short? In this episode, Dr. Robert Cykiert, founder, creator & host of #DoctorPodcasts, sits down with world-renowned viral hepatitis experts Dr. Tatyana Kushner, M.D. @TatyanaKushner (Weill Cornell Medicine) and Dr. Anu Osinusi, M.D., VP of Virology @GileadSciences, to break down the current state of liver disease, diagnosis, and treatment innovation. We dive deep into the silent differences between Hepatitis A, B, C, D, and E—uncovering how these viruses transmit, who is most at risk, and why Hepatitis B is so difficult to clear because it hides directly inside human DNA. Plus, we explore how Gilead Sciences is leveraging artificial intelligence (AI) to disrupt traditional drug development and collapse 15-year timelines into just a few years to find a functional cure. Video Timeline 0:00 – Introduction: The Global Burden of Viral Hepatitis 2:30 – What is Viral Hepatitis & How It Damages the Liver 4:04 – Shocking Global Statistics: Millions Affected Worldwide 4:54 – Gilead Sciences' Evolving Role in Fighting Liver Diseas 6:58 – Hepatitis A vs. B, C, D, & E: Key Differences Explained 7:14 – Modes of Transmission: Bloodborne vs. Fecal-Oral Routes 11:33 – Debunking Misconceptions: Can Saliva Transmit Hepatitis? 12:26 – Gilead's Current Research Priorities (HBV, HCV, HDV) 15:56 – The WHO 2030 Elimination Goal: Where Do We Stand? 17:27 – Screening Recommendations & Universal Pregnancy Testing20:12 – Addressing Hepatitis Delta: "The Forgotten Virus" 24:54 – Why Newborns & Immunosuppressed Patients Face Severe Risks 27:19 – Vaccine Guide: Who Needs the Hepatitis A & B Vaccines? 30:34 – Why Is Hepatitis B So Difficult to Eradicate? (DNA Integration) 33:10 – The Decline of Liver Transplants Due to Hepatitis C Cures 34:24 – The Next Frontier: Functional Cures for Hepatitis B37:41 – How Artificial Intelligence (AI) is Revolutionizing Drug Discovery40:46 – Trusted Online Resources for Patients & Families #HepatitisBCure #LiverHealth #MedicalAI #GileadSciences #PublicHealth #HepatitisAwareness

    Show More Show Less
    43 mins
  • The Next Global Threat? Top Experts on Africa’s New 2026 Ebola Strain. No cures, no vaccines.
    Jun 23 2026

    Is a new Ebola outbreak about to outpace the world? In this #DoctorPodcasts episode 151, two of the world's top epidemic responders break down the current crisis in the war-torn Democratic Republic of the Congo (DRC) and Uganda in Africa.Host Dr. Robert Cykiert, M.D. sits down with "Ebola Czar" Dr. Tolbert Nyenswah (Director of Public Health Emergency Management at Africa CDC) and frontline expert Dr. Daniel Bausch to discuss the Bundibugyo Ebola virus species. Discover why this rare strain currently lacks an effective vaccine, how active armed conflict is stalling contact tracing, and what the global community must do to stop a regional crisis from turning into a global threat. If you want to stay informed on global health security, please LIKE this video, SUBSCRIBE to the channel, and hit the NOTIFICATION BELL! Thanks.(Timestamps)0:00 - Introduction & US CDC Collaboration (p. 1)0:52 - Meet the Top Ebola Experts: Dr. Nyenswah & Dr. Bausch (pp. 1, 3)4:10 - Dr. Nyenswah’s Journey to Becoming the "Ebola Czar" (pp. 2-3)5:36 - Managing the Devastating 2014 West Africa Epidemic (pp. 2, 4)6:38 - How the Current DRC Outbreak Compares to 2014 (p. 5)8:45 - Frontline Realities: 50 Patients, 2 Doctors, No Vaccines (pp. 5-6, 8)12:07 - Busting Myths: How Ebola Actually Transmits (pp. 8-9)14:09 - Where the Current Epidemic Started & Major Cost Drivers (pp. 9-10)16:04 - The Critical Role (and Failure) of Contact Tracing (pp. 10-11)18:07 - Death Tolls: 2014 vs. Present Trajectory (p. 12)20:48 - The Bundibugyo Strain: Why There is No Vaccine (pp. 13-14)24:02 - Clinical Symptoms & The Power of Supportive Care (pp. 15-16)27:16 - Culture vs. Virus: Safe and Dignified Burial Practices (pp. 17, 20)33:54 - Africa CDC & WHO: A Unified Continental Plan (pp. 21-22)36:23 - Playing Catch-Up: Is the Outbreak Outpacing Us? (p. 23)40:08 - The Kenya Quarantine Center Controversy (pp. 25-26)46:10 - Civil Unrest & Broken Public Health Systems (pp. 29-30)49:43 - Can We Control It? A Call for Boots on the Ground (pp. 31-32) #EbolaOutbreak #GlobalHealth #MedicalPodcast #robertcykiertmd

    Show More Show Less
    53 mins
  • The Future of Weight Loss Drugs: Survodutide & Retatrutide. Ozempic & Mounjaro are only the beginning.
    Jun 13 2026

    In this #DoctorPodcasts Episode 149, we sit down with physician, Professor Carel le Roux, a global authority in metabolic medicine, #obesity and #diabetes to discuss the revolutionary shift in anti-obesity medications. We break down the differences between current leading GLP-1 drugs like #Ozempic (semaglutide) and #Mounjaro (tirzepatide), and look ahead to next-generation treatments. Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials. We also explore Eli Lilly’s upcoming triple agonist, Retatrutide. If you want to understand the future of weight loss, #MetabolicHealth, and how these drugs target the brain-gut axis, this deep dive is for you.0:00 - Introduction & Guest Overview0:34 - Episode Welcome: Dr. Robert Cykiert0:48 - Entering Dublin: The GLP-1 Breakthrough2:27 - Long-Term Health Hazards of Obesity & Diabetes3:24 - Why Obesity is a Disease of the Brain, Not Willpower4:57 - Ozempic (Semaglutide) vs. Mounjaro (Tirzepatide)6:16 - The Fatty Liver Disease (MASLD/MASH) Epidemic7:50 - The Truth About Visceral vs. Ectopic Fat10:04 - Survodutide Explained: The New Dual Agonist12:45 - Managing Side Effects & Titration Schedules15:37 - Boehringer Ingelheim & the Future of Obesity Medicine16:48 - Retatrutide: Eli Lilly’s New Triple Agonist18:26 - A 30-Second Guide for Doctors & Patients20:11 - Closing Thoughts & Patient Transformations

    Show More Show Less
    21 mins
  • Excellent Vision Without Glasses After Cataract Surgery: New Johnson & Johnson TECNIS PureSee IOL.
    May 31 2026

    Cataract surgery just entered a golden age with the recent historic FDA approval of the Johnson & Johnson (J&J) TECNIS PureSee IOL (intraocular lens). In Episode 146 of the @DoctorPodcasts Show, host Dr. Robert Cykiert speaks with world-renowned cataract surgeon, Dr. Eric Donnenfeld, and J&J Vision Senior Medical Director and ophthalmologist, Dr. Brian Schwam, to break down this major milestone. If you or a loved one suffer from blurry vision, halos and glare due to cataracts, standard monofocal IOL lenses often lock you into wearing reading glasses all the time. The J&J Tecnis PureSee represents a massive premium IOL leap forward—using a purely refractive design rather than older diffractive rings. This allows patients to maintain maximum contrast sensitivity and crisp vision across all distances - distance, intermediate and near - without losing light intensity, contrast and brightness. Discover why 97% of PureSee patients recommend this treatment and whether you are a prime candidate for this IOL lens. Subscribe to The DoctorPodcasts Show for frequent medical expert insights!

    #Cataract

    #Tecnis

    #EyeHealth

    #Ophthalmology

    #DoctorPodcasts

    #PureSee


    Important Safety Information: https://jjvision.com/en-us/safety-information/?tab=4


    0:00 - Introducing the J&J Tecnis PureSee Lens Breakthrough 0:21 - Welcome to The Doctor Podcast Show Ep. 146

    1:03 - Meet Expert Pioneers Dr. Donnenfeld & Dr. Schwam 3:16 - What is a Cataract and Why Do We Get Them?

    4:23 - Main Symptoms: Blurry Vision, Glare, and Halos

    5:21 - Standard Monofocal Lenses vs. Premium Options

    8:52 - How Multifocal and Extended Depth of Focus (EDOF) Work 10:09 - The Biggest Trade-offs of Older Eye Implants

    11:55 - Rigorous FDA Clinical Trials Criteria Explained

    15:21 - Refractive vs. Diffractive Design: Stopping Light Splitting 17:41 - Over 500,000 Safe International Implantations

    22:26 - Real-World Evidence & High Patient Satisfaction

    23:24 - Who is a Good Candidate for the PureSee Lens?

    25:36 - 25 Years of Innovation at J&J Vision 27:32 - Final Expert Advice: Choosing the Right Ophthalmologist 29:10 - The Future of Eye Care: AI and Robotic Cataract Surgery

    Show More Show Less
    32 mins
  • Revolutionizing Medical Education to Prepare Future-Ready Physicians in the AI Age
    May 22 2026

    DoctorPodcasts video podcast EPISODE 148:Watch David L. Battinelli M.D, , Dean of the Zucker School of Medicine and Physician-in-Chief of Northwell Health in Long Island, NY, co-author of a new book, Revolutionizing Medical Education: A Proven Blueprint to Transform Curricula and Prepare Future-Ready Physicians, discuss how to change traditional medical school curricula to prepare physicians for modern medicine in the AI age. Book information at: https://www.wiley.com/en-us/Revolutionizing+Medical+Education%3A+A+Proven+Blueprint+to+Transform+Curricula+and+Prepare+Future-Ready+Physicians-p-9781394416042 Dr. Battinelli information at: https://faculty.medicine.hofstra.edu/1484-david-battinelli#DoctroPodcasts is the leading physician-hosted video podcast that informs, inspires and builds trust in healthcare and medicine. Watch all 148 episodes of the DoctorPodcasts || Cykiert Files video podcast interview show with physicians, scientists, healthcare specialists, entrepreneurs and other experts. Please SUBSCRIBE & FOLLOW @DoctorPodcasts. Please LIKE, REPOST/QUOTE and SHARE the episodes https://www.doctorpodcasts.com/index-of-doctorpodcasts-episodes/.Send questions, comments, suggestions, reviews and messages to @DoctorPodcasts. Thank you. Robert Cykiert, M.D.#AIinMedicine

    #MedicalEducation

    #FutureOfMedicine

    #MedEd

    #HealthcareAI

    #DoctorPodcast

    #MedicalSchool

    #RevolutionizingMedEd

    #HealthTech

    #AIMedicalEducation

    #PhysicianLeadership

    #DigitalHealth

    #MedStudentLife

    #PodcastForDoctors

    #AIinHealthcare

    #DoctorPodcasts

    #FutureDoctors

    #MedicalInnovation

    #CykiertFiles

    #healthcareleadership #hofstra #northwell

    #battinelli

    Show More Show Less
    33 mins
  • Hantavirus, cruise ships and rats. What you must know.
    May 20 2026

    Deadly #Hantavirus just killed 3 people on a cruise ship. It’s the rare strain that spreads between humans. Top Hantavirus expert Dr. Steven Bradfute breaks down the virus details, prevention, symptoms, treatment, & what you need to know about rats and cruise ships.


    Watch all 147 episodes of the #DoctorPodcasts || Cykiert Files video podcast interview show with physicians, scientists, healthcare specialists, entrepreneurs and other experts https://www.doctorpodcasts.com/index-of-doctorpodcasts-episodes/. Please SUBSCRIBE & FOLLOW @DoctorPodcasts. Please LIKE, REPOST/QUOTE and SHARE the episodes. Send questions, comments, suggestions, reviews and messages to @DoctorPodcasts. Thank you. Robert Cykiert, M.D.


    #Hantavirus

    #HantavirusOutbreak

    #CruiseShipHantavirus

    #AndesVirus

    #HantavirusPulmonarySyndrome

    #RodentBorneVirus

    #DeadlyCruiseShipVirus


    #HantavirusPrevention


    #DrStevenBradfute

    #DoctorPodcasts

    #HealthPodcast

    #ViralOutbreak2026

    #CruiseShipSafety

    #RatVirusAlert

    #EmergingInfectiousDisease

    #robertcykiert

    #robertcykiertmd

    #virus #rats

    #rodents

    Show More Show Less
    38 mins
  • Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease.
    May 11 2026

    Got dry mouth, dry eyes, joint pains, chronic fatigue? Get checked for often-undiagnosed Sjögren’s Disease. Watch this video podcast with rheumatologist & Sjogren's expert, Sara McCoy, M.D. discussing Novartis #ianalumab FDA Breakthrough Therapy Designation. More information is available at: https://www.novartis.com/news/media-releases/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-sjogrens-diseaseandhttps://sjogrens.org/andhttps://www.uwhealth.org/providers/sara-s-mccoy-mdandhttps://www.novartis.com/us-en/patients-and-caregiversWatch all 145 episodes of the #DoctorPodcasts || Cykiert Files video podcast interview show with physicians, scientists, healthcare specialists, entrepreneurs and other experts http://Doctorpodcasts.com/index-of-doctoof-doctoof-doctoof-doctorpodcasts-episodes. Please SUBSCRIBE & FOLLOW @DoctorPodcasts . Please LIKE, REPOST/QUOTE and SHARE the episodes. Send questions, comments, suggestions, reviews and messages to @DoctorPodcasts. Thank you. Robert Cykiert, M.D.#Sjogrens

    #SjogrensSyndrome

    #SjogrensDisease

    #Autoimmune

    #AutoimmuneDisease

    #Rheumatology

    #DryEyesDryMouth

    #ChronicFatigue

    #InvisibleIllness

    #ChronicIllness

    #RareDiseaseAwareness

    #BreakthroughTherapy

    #PatientEducation

    #MedicalPodcast

    #HealthPodcast

    #WomenAndAutoimmunity

    #LivingWithSjogrens

    #RheumLife

    Show More Show Less
    45 mins
  • Want to ditch your reading glasses & bifocals?
    Apr 29 2026

    New, FDA-approved YUVEZZI eye drops made by Tenpoint Therapeutics, are changing how we treat age-related presbyopia, or difficulty with close-up reading vision. Two top eye doctors reveal how this unique 2-ingredient eye drop gives you sharp near and reading vision, without surgery. Watch DoctorPodcasts Episode 144 for more information. Check out https://www.yuvezzi.com and https://tenpointtherapeutics.com for details.

    #DoctorPodcasts

    #YUVEZZI

    #presbyopia #readingglassespodcast #glasses #YUVEZZIEyeDrops

    #DitchReadingGlasses

    #NoMoreBifocals

    #PresbyopiaTreatment

    #FDAApprovedEyeDrops

    #VisionWithoutSurgery

    #CykiertFiles

    #RobertCykiertMD

    #EyeHealth

    #Ophthalmology

    #NonSurgicalVision

    #medicalinnovation #doctorpodcasts #blurry

    #bifocals

    #contactlenses #carbachol

    #brimonidine

    #optometrist

    #ophthalmologist


    Show More Show Less
    30 mins